Retirement Systems of Alabama Acquires 239 Shares of United Therapeutics Co. (NASDAQ:UTHR)

Retirement Systems of Alabama raised its holdings in United Therapeutics Co. (NASDAQ:UTHR) by 0.2% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 129,611 shares of the biotechnology company’s stock after acquiring an additional 239 shares during the period. Retirement Systems of Alabama owned about 0.29% of United Therapeutics worth $45,732,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of the business. USA Financial Formulas bought a new stake in shares of United Therapeutics during the third quarter worth about $33,000. Brooklyn Investment Group bought a new stake in shares of United Therapeutics during the third quarter worth about $33,000. Capital Performance Advisors LLP bought a new stake in shares of United Therapeutics during the third quarter worth about $82,000. MassMutual Private Wealth & Trust FSB grew its holdings in shares of United Therapeutics by 31.9% during the fourth quarter. MassMutual Private Wealth & Trust FSB now owns 240 shares of the biotechnology company’s stock worth $85,000 after purchasing an additional 58 shares during the last quarter. Finally, Values First Advisors Inc. bought a new stake in shares of United Therapeutics during the third quarter worth about $90,000. Institutional investors own 94.08% of the company’s stock.

Insider Transactions at United Therapeutics

In related news, Director Louis W. Sullivan sold 26,209 shares of the company’s stock in a transaction on Wednesday, December 18th. The stock was sold at an average price of $373.22, for a total transaction of $9,781,722.98. Following the completion of the sale, the director now owns 5,051 shares in the company, valued at approximately $1,885,134.22. This represents a 83.84 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, COO Michael Benkowitz sold 10,000 shares of the company’s stock in a transaction on Monday, February 3rd. The stock was sold at an average price of $353.64, for a total value of $3,536,400.00. Following the sale, the chief operating officer now owns 2,577 shares of the company’s stock, valued at $911,330.28. This trade represents a 79.51 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 143,838 shares of company stock valued at $53,981,956 over the last ninety days. 11.90% of the stock is owned by company insiders.

Analyst Upgrades and Downgrades

Several analysts have recently weighed in on the company. UBS Group boosted their price target on United Therapeutics from $415.00 to $475.00 and gave the stock a “buy” rating in a report on Wednesday, January 8th. Oppenheimer lifted their price objective on United Therapeutics from $575.00 to $600.00 and gave the stock an “outperform” rating in a research note on Thursday, October 31st. HC Wainwright lifted their price objective on United Therapeutics from $400.00 to $425.00 and gave the stock a “buy” rating in a research note on Thursday, October 31st. StockNews.com raised United Therapeutics from a “buy” rating to a “strong-buy” rating in a research note on Thursday, January 16th. Finally, Argus lifted their price objective on United Therapeutics from $360.00 to $400.00 and gave the stock a “buy” rating in a research note on Thursday, October 31st. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating, twelve have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $378.36.

United Therapeutics Stock Down 0.3 %

Shares of NASDAQ:UTHR opened at $353.43 on Wednesday. United Therapeutics Co. has a twelve month low of $208.62 and a twelve month high of $417.82. The stock’s 50 day moving average is $364.28 and its 200-day moving average is $357.68. The firm has a market capitalization of $15.78 billion, a price-to-earnings ratio of 15.52, a PEG ratio of 0.92 and a beta of 0.57.

United Therapeutics Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.